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Neoplasm metastasisAbstract Objective: To review follow-up imaging after equivocal bone scans in men with
castration resistant prostate cancer (CRPC) and examine the characteristics of equivocal bone
scans that are associated with positive follow-up imaging.
Methods: We identified 639 men from five Veterans Affairs Hospitals with a technetium-99m
bone scan after CRPC diagnosis, of whom 99 (15%) had equivocal scans. Men with equivocal
scans were segregated into “high-risk” and “low-risk” subcategories based upon wording in
the bone scan report. All follow-up imaging (bone scans, computed tomography [CT], magnetic
resonance imaging [MRI], and X-rays) in the 3 months after the equivocal scan were reviewed.
Variables were compared between patients with a positive vs. negative follow-up imaging after
an equivocal bone scan.
Results: Of 99 men with an equivocal bone scan, 43 (43%) received at least one follow-up im-
aging test, including 32/82 (39%) with low-risk scans and 11/17 (65%) with high-risk scans
(p Z 0.052). Of follow-up tests, 67% were negative, 14% were equivocal, and 19% were posi-
tive. Among those who underwent follow-up imaging, 3/32 (9%) low-risk men had
metastases vs. 5/11 (45%) high-risk men (p Z 0.015).
Conclusion: While 19% of all men who received follow-up imaging had positive follow-up imag-
ing, only 9% of those with a low-risk equivocal bone scan had metastases versus 45% of those
with high-risk. These preliminary findings, if confirmed in larger studies, suggest follow-up im-
aging tests for low-risk equivocal scans can be delayed while high-risk equivocal scans should
receive follow-up imaging.
ª 2019 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Metastatic evaluations for castration-resistant prostate
cancer (CRPC) routinely rely on technetium-99m (99mTc)
bone scintigraphy for identifying bone metastases, in
order to guide clinical decision-making. Roughly one in
four bone scans, however, is equivocal: Neither definitive
for metastases nor definitively normal [1]. Though treat-
ment options for non-metastatic CRPC patients have
advanced some in recent years, determining whether
these equivocal lesions are likely to be metastases is
crucial, considering that there continue to be vast dif-
ferences in prognosis and treatment options for metasta-
tic vs. non-metastatic CRPC [2].
Despite this, few studies have examined characteristics
of equivocal 99mTc bone scans that may correspond to a
greater or lesser risk of a future positive scan. Furthermore,
no guidelines exist regarding whether or not to conduct
repeat imaging after an equivocal bone scan or which type
of imaging test should follow an equivocal bone scan.
To address this limitation in the literature, we reviewed
follow-up imaging tests after an equivocal 99mTc bone scan
in men with M0 CRPC (meaning a patient had no distant
metastasis at the time of castration-resistance) and
examined factors associated with metastases on follow-up
imaging. We considered demographic and clinical vari-
ables such as prostate-specific antigen (PSA) and PSA
doubling time (PSADT) at the time of equivocal bone scan,
as well as aspects of the equivocal bone scan itself, such as
the language used in the radiology report pertaining to the
likelihood of metastases.2. Materials and methods
2.1. Data collection
After obtaining approval from the Institutional Review
Board of the Durham Veterans Affairs Health Care Sys-
tem, we identified 1191 patients with M0 CRPC being
treated at Veterans Affairs Hospitals in five cities in the
United States (Durham, North Carolina; Augusta, Georgia;
San Diego, California; San Francisco, California; West Los
Angeles, California) between 2000 and 2015. CRPC was
defined per the PSA Working Group 2 criteria: A 25% PSA
increase and an absolute 2 ng/mL increase from the
post-androgen deprivation therapy (ADT) nadir while
being castrated [3]. Patients with metastases prior to
CRPC were not included in order to limit the study to M0
CRPC patients. We defined castration as a testosterone
level of <1.74 nmol/L, a bilateral orchiectomy, or the
continuous receipt of a luteinizing hormone-releasing
hormone (LHRH) agonist or antagonist. Detailed
methods on the selection of our M0 CRPC population have
been published previously [4]. Once patients with M0
CRPC were identified, we collected information on de-
mographic, clinical, and pathological characteristics, as
well as all imaging after M0 CRPC diagnosis from their
electronic medical records. Of the 1 191 men with M0
CRPC, 836 (70%) had at least one imaging test after
diagnosis of M0 CRPC. Of these, 639 (76%) had one or
more 99mTc bone scans of which 99 (15%) had a bone scan
that was equivocal for metastases. For patients with
more than one equivocal bone scan, only the first
244 B.T. Hanyok et al.equivocal scan was included. Charts were reviewed to
find all follow-up imaging (bone scan, computed tomog-
raphy [CT], magnetic resonance imaging [MRI], and/or X-
ray targeted to the suspicious lesion) pertaining to the
equivocal lesions within 3 months of the equivocal scan.
Imaging tests were ordered at the discretion of the
treating physician.
Bone scans and all follow-up imaging tests were coded by
trained personnel as positive, equivocal, or negative for me-
tastases based upon the language of the radiology report,
similar to previous studies of equivocal bone scans [1,5].
Personnel were blinded to follow-up imaging when deter-
mining the protocols for categorizing the language of imaging
reports. An imaging report was considered negative if it did
not mention metastases or if it stated that no metastases
were present. A report was considered positive if it stated
thatmetastaseswere present or ifmetastaseswere described
as being at least possible and no alternative diagnosis was
mentioned. Scans where metastases were the only option put
forth by the radiologist were considered positive. An imaging
report was considered equivocal if two or more possible di-
agnoses including metastases were mentioned, or if the im-
aging report was otherwise interpreted as being inconclusive
for metastases (e.g. “these findings are of unknown signifi-
cance and would be an unusual presentation of metastatic
disease”) (additional examples are provided in Appendix 1). In
addition, we created two subcategories of equivocal bone
scan reports, “high-risk” equivocal and “low-risk” equivocal,
to distinguish between radiology reports of equivocal bone
scans that were inconclusive but suggested a high likelihood
of metastases (e.g. “.suspicion for a metastasis, although it
could also represent degenerative change”), and those which
were inconclusive but suggested a low likelihood of metas-
tases (e.g. “.more suggestive of Paget’s disease than mets,
although the latter or a combination of both cannot be
excluded”). These categories are defined further in Appendix
1. Patients receivingmultiple follow-up imaging tests in the 3-
month window after the equivocal scan were considered as
positive for metastases if any positive imaging was found.
Equivocal follow-up imaging tests were considered negative
for analysis.
2.2. Statistical analysis
PSADTwascalculatedbydividing thenatural logof two (0.693)
by the slope of the linear regression of the natural log of PSA
over time in months. PSADTwas calculated using all available
PSA values in the two years leading up to the equivocal bone
scan, or starting at the time of CRPC diagnosis if the equivocal
scan occurred within 2 years of CRPC diagnosis.
Patient characteristics were summarized among all men
who had an equivocal bone scan as well as those who had
follow-up imaging within 3 months, stratified by follow-up
imaging test results, using median, 25th and 75th percen-
tiles for continuous variables and frequencies and per-
centages for categorical variables. The association between
clinical and demographic factors and follow-up imaging test
result was tested using Wilcoxon rank sum tests for
continuous variables and Fisher’s exact test for categorical
variables. Similarly, characteristics were compared be-
tween those who received follow-up imaging vs. those whodid not. Factors that were tested included age (contin-
uous), year of equivocal bone scan (continuous), PSA at
time of equivocal bone scan (continuous, log-transformed),
PSADT leading up to equivocal bone scan (continuous), risk
rating of the equivocal scan (high-risk vs. low-risk), and
whether the follow-up scan was within 1 week (yes vs. no).
We tabulated the number of each follow-up imaging test
performed (X-ray, CT, MRI, bone scan) and the number of
these that were positive for metastases. Of note, patients
with multiple follow-up imaging tests were counted more
than once in this analysis. The proportion of positive follow-
up imaging following a low-risk equivocal bone scan was
compared to that of high-risk scans.
Analyses were performed using Stata 12.1 (Stata, Corp.,
College Station, TX, USA). The p < 0.05 was used to indi-
cate statistical significance.
3. Results
Of 639 men who received at least one 99mTc bone scan after
diagnosis of M0 CRPC, 99 (15%) had an equivocal bone scan.
The median age of these 99 patients was 78 years, and 39%
of patients were African American (Table 1). Median PSA
prior to equivocal scan was 9.2 ng/mL, and median PSADT
leading up to equivocal scan was 11.0 months, among those
patients with sufficient PSA values to calculate doubling
time (nZ 74). Follow-up imaging tests were ordered for 43
(43%) of the 99 men, including 32 (39%) of the 82 men with
low-risk equivocal bone scans and 11 (65%) of the 17 men
with high-risk equivocal bone scans (p Z 0.052). Patients
who received a follow-up imaging test had similar age,
year, race, PSA, PSADT, and risk rating of equivocal scan
compared to patients who did not receive follow-up imag-
ing (p > 0.05, data not shown). Of all follow-up imaging
tests, 67% were negative, 14% were equivocal, and 19%
were positive. Follow-up imaging tests included 32 X-rays,
eight bone scans, five MRIs, and 10 CTs. The number of
scans is greater than the number of men, as nine men
received multiple follow-up imaging tests.
Of the patients who received a follow-up imaging test,
eight (19%) had a positive follow-up imaging test (Table 2).
Among 32 men with a low-risk equivocal bone scan and
subsequent follow-up imaging, only three (9%) had follow-up
imaging that was positive for metastases. In contrast, of 11
men with a high-risk equivocal bone scan and follow-up
imaging, five (45%) had metastases on follow-up imaging.
Patients with high-risk equivocal bone scans were more
likely to have metastases on follow-up imaging compared to
patients with low-risk equivocal scans (45% vs. 9%,
p Z 0.017). Median PSADT was 11.1 months (Q1eQ3:
6.2e15.8) among men with negative follow-up imaging and
16.7 months (Q1eQ3: 4.4e28.8) among men with positive
follow-up imaging; however, no statistically significant dif-
ference was detected (pZ 0.608). Similarly, median PSA at
equivocal bone scan was 7.9 ng/mL (Q1eQ3: 5.4e14.8)
among men with negative follow-up imaging and 14.4 ng/mL
(Q1eQ3: 9.6e27.8) among men with positive follow-up im-
aging, but the difference was not statistically significant
(p Z 0.086). No statistically significant differences were
detected between follow-up imaging result and age, year,
or follow-up scan within 1 week (all p > 0.6).
Table 1 Patient characteristics at time of equivocal bone
scan.
Characteristic Data (n Z 99)
Age (year) 78 (69e84)
Year 2006 (2004e2010)
Race
non-African American 60 (61%)
African American 38 (39%)
PSA (ng/mL) 9.2 (4.8e21.2)
PSADTa (month) 11.0 (5.1e27.6)
Risk rating of equivocal scan
Low 82 (83%)
High 17 (17%)




Type of follow-up imagingb
X-ray 32 (58%)
Bone scan 8 (15%)
MRI 5 (9%)
CT 10 (18%)
Table displays median (25th percentile, 75th percentile) for
continuous variables and frequencies (%) for categorical vari-
ables. CT, computed tomography; MRI, magnetic resonance
imaging; PSA, prostate-specific antigen; PSADT, prostate-
specific antigen doubling time.
a Among 74 patients with sufficient PSA values to calculate
doubling time.
b Total count of follow-up imaging tests is greater than the
number of men who received follow-up imaging, as nine men
received multiple follow-up imaging tests.
Table 3 Type of follow-up imaging test and outcome
stratified by low- and high-risk.
Type Low-risk High-risk
positive/performed (%) positive/performed (%)
X-ray 2/25 (8) 1/7 (14)
Bone scan 2/6 (33) 1/2 (50)
MRI 1/3 (33) 1/2 (50)
CT 1/7 (14) 2/3 (67)
CT, computed tomography; MRI, magnetic resonance imaging.
Equivocal bone scans in CRPC patients 245Overall, each follow-up imaging modality was more
likely to be positive among those with a high-risk equivocal
bone scan rating vs. those with low-risk rating (Table 3).
However, regardless of risk-rating, men receiving X-rays
had a low rate of positive follow-up imaging, although
numbers were small (14% positive).Table 2 Associations between clinical factors and follow-up im
Clinical factors Fo
Negative, n Z 3
Age (year) 80 (71e84)
Year 2006 (2004e2010
PSA (ng/mL) 7.9 (5.4e14.8)
PSADTa (month) 11.1 (6.2e15.8)
High-risk equivocal bone scan rating
Low 29 (91%)
High 6 (55%)
Follow-up scan within 1 week
No 29 (81%)
Yes 6 (86%)
Table displays median (25th percentile, 75th percentile) for continuo
p-Value calculated using Fisher’s exact test or rank sum test.
PSA, prostate-specific antigen; PSADT, prostate-specific antigen doub
a Data only available on 33 patients.4. Discussion
Equivocal bone scans are common for men with M0 CRPC,
occurring in 15% of the men in our study. Despite this, there
are no clear follow-up imaging guidelines for M0 CRPC pa-
tients with equivocal scans. While detecting metastases is
crucial for clinical decision-making, few studies have
examined predictors of positive follow-up imaging after an
equivocal bone scan. Only 43% of men in the current study
who had equivocal bone scans received targeted follow-up
imaging within 3 months. Of these men, 19% were diag-
nosed with metastases on follow-up imaging. The only
factor related to positive follow-up imaging was a “high-
risk” rating based on interpretation of the equivocal bone
scan radiology report. Among those who underwent repeat
imaging, only 9% of patients with a low-risk equivocal bone
scan had metastases, whereas 45% of those with high-risk
equivocal bone scans had metastases. While numbers are
small and require confirmation, if validated, these findings
suggest follow-up imaging tests for men with low-risk
equivocal scans can be delayed while high-risk equivocal
scans should receive follow-up imaging.
In our study of men with M0 CRPC receiving one or more
bone scans within the United States Veterans Affairs Health
Care System, the rate of equivocal 99mTc bone scans was 15%.
This is in line with previous studies, which reported rates of
equivocal scans ranging from 14% to 56% among various co-
horts of patients being treated for prostate cancer, with mostaging test outcome.
llow-up imaging test result p-Value
5 (81%) Positive, n Z 8 (19%)
71 (67e78) 0.091









us variables and frequencies (%) for categorical variables.
ling time.
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fewer than 10 equivocal scans) [1,5e9]. However, most of
these studies examined men with either newly diagnosed
prostate cancer or men with rising PSA after primary therapy.
No prior study has examined the rate of equivocal bone scans
in the castration-resistant population. Thus, it is difficult to
directly compare rates across studies; nonetheless, our rate
of equivocal scans was similar to prior studies.
Among the 99 patients with an equivocal bone scan in
our study, 43 (43%) received follow-up imaging of the
equivocal lesion(s) within 3 months. Most prior studies of
equivocal bone scans did not evaluate the frequency of
follow-up imaging after equivocal bone scans or were pro-
spective studies with protocol-mandated follow-up imaging
for all patients (i.e. 100% follow-up imaging). However, one
observational study of newly diagnosed patients reported
that 60% of patients with equivocal bone scans received
additional imaging within 6 weeks before or after the
equivocal bone scan, with the majority occurring after the
bone scan [1]. This is very similar to the rate of follow-up
imaging we found for men with high-risk equivocal scans
(65%). In contrast, the low rate of follow-up imaging for
men with low-risk equivocal scans (39%) in the current
study suggests perhaps that clinicians who treated these
patients viewed these scans as negative rather than
equivocal with no immediate follow-up required.
Of 43 patients in our study with follow-up imaging after
an equivocal bone scan, eight (19%) had metastases on
follow-up imaging, including three (9%) of 32 patients with
low-risk equivocal scans and five (45%) of 11 patients with
high-risk equivocal scans. Prior studies have suggested that
the rate of finding metastases among men with an equiv-
ocal bone scan ranges from 14% to 62% [1,6e9]. This wide
range likely reflects the diverse methods used for follow-up
imaging, small sample sizes, and significant differences
among the patient populations being studied, none of
which were limited to castration-resistant men, though in
general, these results were in line with our findings.
Few prior studies examined factors associated with
positive follow-up imaging after an equivocal bone scan. In
our study, the lack of association between PSA and PSADT
and a positive follow-up imaging test was somewhat sur-
prising considering the strong link between PSA, PSADT, and
bone metastases seen in other settings, including predict-
ing positive imaging in the initial bone scan in our cohort
[4,10e12]. Though these findings may relate to the limited
number of patients, nonetheless, given that standard var-
iables (i.e. PSA, PSADT) were not associated with positive
follow-up imaging, we evaluated the wording within the
bone scan report. Our finding that “high-risk” equivocal
bone scans are more likely than “low-risk” equivocal bone
scans to be followed by a positive imaging test is unsur-
prising, but may be very clinically useful. While some cli-
nicians may have access to dedicated genitourinary
radiologists who can provide direction following an equiv-
ocal bone scan, clinicians lacking this resource may find the
distinction between high-risk and low-risk equivocal bone
scans to be a helpful “rule of thumb”. Specifically, if the
high-risk vs. low-risk distinction is confirmed in future
studies, this suggests follow-up imaging tests for men with
low-risk equivocal scans may be delayed while high-risk
equivocal scans should receive follow-up imaging.While our data provide some insight into which patients
have a high risk of positive follow-up imaging after an
equivocal bone scan and should thus receive immediate
follow-up imaging, the question of which imaging modality
should follow an equivocal bone scan is less clear. Although
the small sample size of the study prevents us from making
strong conclusions, plain film radiographs (X-rays) were not
often positive for metastases with only 8% positive in the
low-risk group and 14% in the high-risk group. The other
tests (bone scan, MRI, CT) were more likely to show me-
tastases with all being roughly equally likely to be positive.
These findings suggest that follow-up imaging with plain X-
rays is less helpful and that using cross sectional imaging
(CT or MRI) for follow-up imaging is more likely to be
diagnostic, though this requires further study in larger data
sets. Importantly, the field of imaging for prostate cancer is
rapidly evolving and thus, the best technique(s) for both
initial scan and follow-up after an equivocal bone scan
remain unclear [13].
This study looks at imaging that took place from 2000 to
2015. More recent imaging techniques, such as whole-body
MRIs and Gallium-68 prostate-specific membrane antigen
(PSMA) positron emission tomography (PET)/CT imaging,
which were not widely used in prostate cancer staging for
the majority of the period of the study, were not included
in the analysis. Ideally, future studies would apply these
methods to results from new imaging modalities to evaluate
factors that may indicate a higher risk of positive imaging
after an equivocal PET scan or full-body MRI, though the
higher sensitivity of these techniques may mean that
overall number of equivocal scans is reduced [14,15].
Our study has several limitations. First, since this was an
observational study, not all patients had follow-up imaging,
and patients who did have follow-up imaging were not a
random sample of those with equivocal bone scans. The as-
sociations that were found do not take into account the
probability that a patient receives a follow-up scan or any
possible confounders. Furthermore, the follow-up imaging
tests did not always evaluate all of the equivocal lesions that
had been described on the equivocal bone scan. This may
lead to underestimation of the rate of positive follow-up
since, and in fact, some of the lesions did not receive follow-
up imaging. In addition, the restriction of follow-up imaging
to tests that occurred within 3 months is somewhat arbitrary.
Patients included in this study received care at five separate
facilities and physician experience and practice may have
varied between sites [16]. Indeed, we have previously pub-
lished on practice patternswithin theMOCRPC space, though
the focus of this study was on identifying which factors can
help guide the follow-up to an equivocal scan [17]. Given this
limitation, future prospective studies are needed to validate
our definition of high-risk vs. low-risk equivocal scans. As this
was an observational study with a small size, it limits the
strengths of the conclusions that can be drawn and may have
influenced some of our more surprising results, such as the
lack of association of PSA and/or PSADT.Moreover, thoughwe
had a sizable percentage of African American, the small
overall numbers precluded us from analyzing race-specific
results. Though we previously found race does not predict
the development of metastases for men with non-metastatic
CRPC, future studies are needed to assess whether race af-
fects the follow-up rate of men with equivocal scans. Also,
Equivocal bone scans in CRPC patients 247given the small numbers, it is possible there are other
important clinical predictors of future scan positivity that we
lacked sufficient power to detect and this should be assessed
in future larger studies [18]. We only reviewed 99mTc bone
scans, but bone scans using sodium fluoride or novel markers
(i.e. PSMA-PET) may be more sensitive and may have detec-
ted fewer equivocal scans. The relationship between newer
modalities such as PET/CT and 99mTc bone scans warrant
further investigation. However, 99mTc bone scans continue to
have widespread use and remain recommended by some
guidelines as front-line tests for detecting bone metastases
[19]. Likewise, none of our follow-up imaging included so-
dium fluoride or novel markers. How this would change the
detection of metastases on follow-up requires further study.
The heterogeneity of the follow-up imaging in itself is also a
limitation, since some types of follow-up imaging, such as X-
rays, may be less sensitive to metastases. Follow-up data
regarding treatments received after the equivocal scan were
not readily available limiting us from assessing whether the
equivocal scan resulted in a change in therapy. Finally, we
were unable to reliably capture information on symptoms
such as bone pain that may have influenced the frequency of
follow-up imaging and the likelihood that the subsequent
imaging would be positive.
5. Conclusion
In summary, we found that 15% of M0 CRPC patients
receiving 99mTc bone scans have at least one equivocal bone
scan, of which only 43% received targeted follow-up imag-
ing within 3 months. While 19% of all men who receivedAppendix 1 Definitions of “low-risk” and “high-risk” ratings of
Definition
High-risk equivocal definition The radiology report ide
more possible diagnoses
that prostate cancer me
more likely than the alte
Low-risk equivocal definition, Part 1 The radiology report ide
more possible diagnoses
that prostate cancer me
likely than the alternativ
Low-risk equivocal definition, Part 2 The radiology report sug
prostate cancer metasta
diagnosis are equally likefollow-up imaging had metastases, only 9% of those with a
low-risk equivocal bone scan had metastases, compared to
45% of those with a high-risk equivocal bone scan. Though
numbers are small, plain X-rays were less likely than other
modalities to be positive when used as a follow-up to an
equivocal bone scan. These preliminary findings suggest
follow-up imaging tests for men with low-risk equivocal
scans can be delayed while high-risk equivocal scans should
receive follow-up imaging, though confirmation in larger
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Example(s)
ntifies two or
, but it suggests
tastases are
rnatives.
(a) “.suspicion for a metastasis,
although it could also represent
degenerative change.”
(b) “.concern is for metastases, how-
ever trauma cannot be excluded.”
(c) “.consistent with metastatic dis-
ease given the patient’s history,
however, the differential diagnosis
does include Paget’s disease.”
ntifies two or
, but it suggests
tastases are less
es.
(a) “This is likely degenerative, however
an early metastasis cannot be
entirely excluded.”
(b) “.may be due to post-traumatic
changes or less likely a small met.”
(c) “.more suggestive of Paget’s dis-
ease than mets, although the latter





“.nonspecific and may result from focal
metastasis or fracture.”
(continued on next page)
Appendix 1 (continued )
Definition Example(s)
Low-risk equivocal definition, Part 3 The radiology report does not
specifically identify prostate cancer
metastases as a possible diagnosis, but it
describes the findings as abnormal in the
context of a prostate cancer metastatic
evaluation.
“Abnormal radiotracer uptake in a linear
vertical configuration within the
sternum.”
Low-risk equivocal definition, Part 4 The radiology report identifies only
prostate cancer metastases as a possible
explanation of abnormal findings, but it
explicitly states that metastases are
unlikely.
“These findings are of unknown
significance and would be an unusual
presentation of metastatic disease.”
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